Tandem Diabetes Care Stock Price Prediction
| TNDM Stock | USD 35.15 2.38 6.34% |
Oversold Vs Overbought
61
Oversold | Overbought |
Quarterly Earnings Growth (0.37) | EPS Estimate Next Quarter (0.19) | EPS Estimate Current Year (1.72) | EPS Estimate Next Year (1.19) | Wall Street Target Price 51.1 |
Using Tandem Diabetes hype-based prediction, you can estimate the value of Tandem Diabetes Care from the perspective of Tandem Diabetes response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Tandem Diabetes using Tandem Diabetes' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Tandem using crowd psychology based on the activity and movement of Tandem Diabetes' stock price.
Tandem Diabetes Short Interest
An investor who is long Tandem Diabetes may also wish to track short interest. As short interest increases, investors should be becoming more worried about Tandem Diabetes and may potentially protect profits, hedge Tandem Diabetes with its derivative instruments, or be ready for some potential downside.
200 Day MA 39.1945 | Short Percent 0.167 | Short Ratio 5.7 | Shares Short Prior Month 6 M | 50 Day MA 33.3111 |
Tandem Diabetes Care Hype to Price Pattern
Investor biases related to Tandem Diabetes' public news can be used to forecast risks associated with an investment in Tandem. The trend in average sentiment can be used to explain how an investor holding Tandem can time the market purely based on public headlines and social activities around Tandem Diabetes Care. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Tandem Diabetes' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Tandem Diabetes.
Tandem Diabetes Implied Volatility | 0.66 |
Tandem Diabetes' implied volatility exposes the market's sentiment of Tandem Diabetes Care stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Tandem Diabetes' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Tandem Diabetes stock will not fluctuate a lot when Tandem Diabetes' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Tandem Diabetes to buy its stock at a price that has no basis in reality. In that case, they are not buying Tandem because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Tandem Diabetes after-hype prediction price | USD 35.51 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Tandem contract
Based on the Rule 16, the options market is currently suggesting that Tandem Diabetes Care will have an average daily up or down price movement of about 0.0413% per day over the life of the 2025-03-21 option contract. With Tandem Diabetes trading at USD 35.15, that is roughly USD 0.0145 . If you think that the market is fully incorporating Tandem Diabetes' daily price movement you should consider acquiring Tandem Diabetes Care options at the current volatility level of 0.66%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Tandem |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Tandem Diabetes' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Tandem Diabetes After-Hype Price Prediction Density Analysis
As far as predicting the price of Tandem Diabetes at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Tandem Diabetes or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Tandem Diabetes, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Tandem Diabetes Estimiated After-Hype Price Volatility
In the context of predicting Tandem Diabetes' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Tandem Diabetes' historical news coverage. Tandem Diabetes' after-hype downside and upside margins for the prediction period are 32.03 and 38.99, respectively. We have considered Tandem Diabetes' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Tandem Diabetes is very steady at this time. Analysis and calculation of next after-hype price of Tandem Diabetes Care is based on 3 months time horizon.
Tandem Diabetes Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Tandem Diabetes is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tandem Diabetes backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Tandem Diabetes, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 3.48 | 0.06 | 0.02 | 10 Events / Month | 2 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
35.15 | 35.51 | 1.02 |
|
Tandem Diabetes Hype Timeline
Tandem Diabetes Care is at this time traded for 35.15. The entity has historical hype elasticity of 0.06, and average elasticity to hype of competition of -0.02. Tandem is forecasted to increase in value after the next headline, with the price projected to jump to 35.51 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 1.02%, whereas the daily expected return is at this time at 0.11%. The volatility of related hype on Tandem Diabetes is about 1651.09%, with the expected price after the next announcement by competition of 35.13. The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 425.41 M. Given the investment horizon of 90 days the next forecasted press release will be in about 10 days. Check out Tandem Diabetes Basic Forecasting Models to cross-verify your projections.Tandem Diabetes Related Hype Analysis
Having access to credible news sources related to Tandem Diabetes' direct competition is more important than ever and may enhance your ability to predict Tandem Diabetes' future price movements. Getting to know how Tandem Diabetes' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Tandem Diabetes may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| DXCM | DexCom Inc | (1.28) | 11 per month | 1.45 | 0.13 | 5.52 | (2.79) | 10.13 | |
| INSP | Inspire Medical Systems | 0.00 | 0 per month | 0.00 | (0.06) | 5.02 | (5.27) | 19.71 | |
| SWAV | Shockwave Medical | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PEN | Penumbra | 0.00 | 0 per month | 1.25 | 0.19 | 3.51 | (2.56) | 11.81 | |
| PODD | Insulet | 0.00 | 0 per month | 0.93 | 0.13 | 3.65 | (1.72) | 12.33 | |
| ABT | Abbott Laboratories | (1.46) | 8 per month | 0.00 | (0.05) | 1.52 | (1.70) | 6.52 | |
| ALGN | Align Technology | 0.00 | 0 per month | 2.25 | 0.02 | 4.22 | (3.18) | 13.52 | |
| SYK | Stryker | 0.00 | 0 per month | 1.06 | 0.04 | 2.18 | (1.88) | 6.19 | |
| ASXC | Asensus Surgical | 0.00 | 10 per month | 2.17 | 0.11 | 4.35 | (4.17) | 55.98 | |
| PACB | Pacific Biosciences of | 0.00 | 0 per month | 0.00 | (0.01) | 10.56 | (9.69) | 26.42 | |
| NNOX | Nano X Imaging | 0.00 | 0 per month | 4.83 | 0.11 | 12.97 | (8.11) | 36.15 | |
| BSX | Boston Scientific Corp | 0.00 | 0 per month | 0.80 | 0.14 | 1.58 | (1.50) | 6.63 | |
| MDT | Medtronic PLC | 0.00 | 0 per month | 0.00 | (0.05) | 1.78 | (2.22) | 5.96 |
Tandem Diabetes Additional Predictive Modules
Most predictive techniques to examine Tandem price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Tandem using various technical indicators. When you analyze Tandem charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Tandem Diabetes Predictive Indicators
The successful prediction of Tandem Diabetes stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Tandem Diabetes Care, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Tandem Diabetes based on analysis of Tandem Diabetes hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Tandem Diabetes's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Tandem Diabetes's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 6.97 | 7.66 | 6.9 | 8.12 | Days Of Inventory On Hand | 104.47 | 151.69 | 174.45 | 176.39 |
Story Coverage note for Tandem Diabetes
The number of cover stories for Tandem Diabetes depends on current market conditions and Tandem Diabetes' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Tandem Diabetes is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Tandem Diabetes' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Tandem Diabetes Short Properties
Tandem Diabetes' future price predictability will typically decrease when Tandem Diabetes' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Tandem Diabetes Care often depends not only on the future outlook of the potential Tandem Diabetes' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tandem Diabetes' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 65 M | |
| Cash And Short Term Investments | 467.9 M |
Check out Tandem Diabetes Basic Forecasting Models to cross-verify your projections. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.82) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.